Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).

Greystoke, A., Oughton, J.B., Brown, S.R. et al. (16 more authors) (2024) Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC). In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. ASCO Publications

Metadata

Item Type: Proceedings Paper
Authors/Creators:
  • Greystoke, A.
  • Oughton, J.B.
  • Brown, S.R.
  • Butterworth, K.
  • Coyle, V.
  • Franks, K.
  • Hassani, A.
  • Harrow, S.
  • Hatton, M. ORCID logo https://orcid.org/0000-0003-2778-7926
  • Hiley, C.T.
  • Kendall, J.
  • Phillip, R.
  • Norris, M.
  • Ojo, O.
  • Shaw, P.
  • Walker, F.
  • Yang, H.
  • Chalmers, A.J.
  • Faivre-Finn, C.
Copyright, Publisher and Additional Information:

© 2024 by American Society of Clinical Oncology
Dates:
  • Published: 1 June 2024
  • Published (online): 29 May 2024
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Depositing User: Symplectic Sheffield
Date Deposited: 28 Aug 2024 15:10
Last Modified: 28 Aug 2024 15:11
Status: Published
Publisher: ASCO Publications
Refereed: Yes
Identification Number: 10.1200/JCO.2024.42.16_suppl.TPS8119
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics


CORE (COnnecting REpositories)